<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124746">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01478555</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-101-001</org_study_id>
    <nct_id>NCT01478555</nct_id>
  </id_info>
  <brief_title>A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease</brief_title>
  <acronym>ISV-101</acronym>
  <official_title>A Dose-Finding Study To Compare The Safety, Tolerability, And Efficacy Of Differing Dosing Regimens Of ISV-101 (Bromfenac In DuraSite® Ophthalmic Solution) To Vehicle And DuraSite Alone In Dry Eye Disease Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSite Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSite Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy in topical
      administration of differing dosing regimens of ISV-101 (Bromfenac in DuraSite® ophthalmic
      solution) compared to Vehicle and DuraSite alone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Dose 1 of Bromfenac in DuraSite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 of Bromfenac in DuraSite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 of Bromfenac in DuraSite</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DuraSite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV 101</intervention_name>
    <description>Bromfenac in DuraSite</description>
    <arm_group_label>Dose 1 of Bromfenac in DuraSite</arm_group_label>
    <arm_group_label>Dose 2 of Bromfenac in DuraSite</arm_group_label>
    <arm_group_label>Dose 3 of Bromfenac in DuraSite</arm_group_label>
    <arm_group_label>DuraSite</arm_group_label>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteers 18 years of age and older who have a diagnosis of moderate to severe dry
             eye disease.

          2. Negative pregnancy test prior to the conduct of any protocol-specific procedure. The
             subject must use effective contraception for the duration of the study. Post
             menopausal is defined as having no menses for at least 12 consecutive months

          3. Signature of the subject on the Informed Consent Form

          4. Willing to avoid disallowed medication for the duration of the study.

          5. Able to self-administer study drug (or have a caregiver available to instill all
             doses of study drug)

          6. Able and willing to follow study instructions

          7. Additional inclusion criteria also apply

        Exclusion Criteria:

          1. Females who are pregnant or nursing. Females of childbearing potential (not
             surgically sterilized or postmenopausal) may not participate in the study if they do
             not agree to use adequate birth control methods for the duration of the study).

          2. Use of contact lenses during the study.

          3. Use of any concomitant topical ocular medications except for artificial tears during
             the dosing period

          4. Presence or history of treatment with systemic immunosuppressive or chemotherapeutic
             agents.

          5. Prior or anticipated concurrent use of an investigational product or device that
             could confound the findings about Dry Eye in the study eye.

          6. A condition or a situation, which in the investigator's opinion may put the subject
             at increased risk, confound study data, or interfere significantly with the subject's
             study participation

          7. Known hypersensitivity to any component of the study drug or procedural medications

          8. Participation in any other clinical trial within 30 days prior to screening

          9. Known hypersensitivity to NSAIDS

         10. Any active corneal epithelial/stromal pathology noted in the study eye at the
             screening visit

         11. Any history of corneal surgery (including corneal crosslinking, radial keratotomy,
             corneal transplant, or LASIK)

         12. Cataract surgery within the past year.

         13. Known contraindication to the study drugs or any of their components
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Judith Hutcheson</last_name>
    <email>jhutcheson@insite.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 2, 2017</lastchanged_date>
  <firstreceived_date>October 24, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
